Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Resverlogix ( (TSE:RVX) ) is now available.
Resverlogix Corp. has received a management cease trade order from the Alberta Securities Commission after missing the March 31 deadline to file its 2025 annual financial statements and related disclosures. The order restricts trading in the company’s securities by its CEO and CFO until two business days after the required annual filings are submitted, while public trading in its common shares remains unaffected.
The company and its external auditor are working to complete the audit and associated filings as soon as possible and intend to follow alternative information guidelines while in default. Resverlogix emphasized it is not subject to insolvency proceedings and reported no undisclosed material changes since its earlier announcements, with management and insiders remaining under an insider trading blackout until the filings are made.
More about Resverlogix
Resverlogix Corp. is a Calgary-based late-stage biotechnology company specializing in epigenetic therapies for chronic diseases. Its lead candidate, apabetalone, targets cardiovascular disease, related comorbidities, and post-COVID-19 conditions, and the company’s shares trade on the Toronto Stock Exchange under the symbol RVX.
Average Trading Volume: 39,695
Technical Sentiment Signal: Sell
Current Market Cap: C$31.59M
See more data about RVX stock on TipRanks’ Stock Analysis page.